<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Aruna Subramanian, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Joanna Nelson, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Emily A Blumberg, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Allyson Bloom, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Mar 23, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nontuberculous mycobacteria (NTM) are ubiquitous in the environment, and approximately 200 species have been identified [
         <a href="#rid1">
          1
         </a>
         ]. Solid organ transplant (SOT) recipients have an increased risk for infection with NTM due to depressed cell-mediated immunity. Although NTM infection rates are low compared with other types of infection, their overall incidence of NTM infections is increasing [
         <a href="#rid2">
          2
         </a>
         ]. NTM infections in transplant recipients can cause significant morbidity and mortality, due in part to difficulties in disease recognition, delayed diagnosis, and complex drug interactions [
         <a href="#rid3">
          3-5
         </a>
         ].
        </p>
        <p>
         This topic reviews NTM infections in solid organ transplant recipients. Tuberculosis (TB) and the evaluation, treatment, and prophylaxis of infection in solid organ transplant recipients, as well as bacterial, viral, and fungal infections in lung transplant recipients, are reviewed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1407.html" rel="external">
          "Tuberculosis in solid organ transplant candidates and recipients"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1398.html" rel="external">
          "Evaluation for infection before solid organ transplantation"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1396.html" rel="external">
          "Infection in the solid organ transplant recipient"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1408.html" rel="external">
          "Prophylaxis of infections in solid organ transplantation"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1395.html" rel="external">
          "Bacterial infections following lung transplantation"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/13952.html" rel="external">
          "Viral infections following lung transplantation"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15396.html" rel="external">
          "Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/8313.html" rel="external">
          "Prevention of cytomegalovirus infection in lung transplant recipients"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1394.html" rel="external">
          "Fungal infections following lung transplantation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most NTM species have been found in soil and water and the majority of infections arise from environmental exposure [
         <a href="#rid6">
          6
         </a>
         ]. Infections were thought not to be transmitted from animal to human or human to human; however, human-to-human spread of
         <em>
          Mycobacterium
         </em>
         <em>
          abscessus
         </em>
         among patients in cystic fibrosis centers and on a population level has been reported [
         <a href="#rid7">
          7-9
         </a>
         ]. It is not clear whether this transmission occurred through direct person-to-person spread or, more likely, environmental contamination through aerosols and fomites [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         In regions where tuberculosis is not endemic, NTM infections are more common in SOT recipients than TB [
         <a href="#rid3">
          3
         </a>
         ]. The exact incidence is difficult to determine since reporting is not mandatory. A large single center study of SOT recipients of all organ types reported an incidence of NTM infection (defined as any positive culture for NTM) of 1.5 percent [
         <a href="#rid10">
          10
         </a>
         ]. Lung transplant recipients have the highest rates of infection, ranging from 0.5 to 8.0 percent, followed by heart transplant recipients, ranging from 0.2 to 2.8 percent [
         <a href="#rid6">
          6,11
         </a>
         ]. By contrast, rates of NTM infection in renal transplant recipients range from 0.16 to 0.38 percent; and, in one series of liver transplant recipients, the rate was 0.04 percent [
         <a href="#rid3">
          3,6
         </a>
         ].
        </p>
        <p>
         The slowly growing mycobacteria
         <em>
          Mycobacterium avium
         </em>
         and
         <em>
          Mycobacterium intracellulare
         </em>
         (together known as
         <em>
          Mycobacterium avium
         </em>
         complex [MAC]) are the most common NTM species to cause infection in the United States and are the most common species isolated after SOT [
         <a href="#rid11">
          11,12
         </a>
         ]. In addition to MAC, there have been approximately 25 species of NTM reported to cause disease in SOT recipients including the slowly growing species
         <em>
          Mycobacterium kansasii
         </em>
         ,
         <em>
          Mycobacterium haemophilum
         </em>
         , and
         <em>
          Mycobacterium marinum
         </em>
         , along with the rapidly growing species
         <em>
          Mycobacterium fortuitum
         </em>
         ,
         <em>
          Mycobacterium chelonae
         </em>
         , and
         <em>
          M. abscessus
         </em>
         (
         <a class="graphic graphic_table graphicRef61936" href="/z/d/graphic/61936.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid3">
          3,5,6
         </a>
         ]. The predominant NTM organism can differ based on transplanted organ. For example,
         <em>
          Mycobacterium abscessus
         </em>
         is the most commonly reported species among lung transplant recipients whereas
         <em>
          Mycobacterium avian
         </em>
         complex and
         <em>
          Mycobacterium kansasii
         </em>
         are most commonly reported NTM species in heart transplant recipients [
         <a href="#rid13">
          13
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5344.html" rel="external">
          "Epidemiology of nontuberculous mycobacterial infections"
         </a>
         .)
        </p>
        <p>
         SOT recipients have an increased risk for infection with NTM due to depressed cell-mediated immunity. A prior single center study identified lung transplant itself as a risk factor for NTM infection [
         <a href="#rid14">
          14
         </a>
         ]. Among lung transplant patients, risk factors for NTM infection include cystic fibrosis (CF) as underlying diagnosis, use of anti-thymocyte globulin for induction immunosuppression, NTM disease or colonization pre-transplant, and single lung transplant [
         <a href="#rid15">
          15,16
         </a>
         ]. A recent multi-national case control study evaluated risk factors for NTM infection in solid organ transplant recipients of all organ types and found that older age at time of transplant, recent hospital admission within the past 90 days, receipt of antifungals, and receipt of lymphocyte depleting antibodies were associated with increased risk of NTM infection [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
         Outbreaks related to environmental or nosocomial exposure have been described in SOT recipients. A report of a biphasic outbreak of
         <em>
          M. abscessus
         </em>
         in 126 patients included 70 SOT recipients and was associated with a contaminated water source at a tertiary care hospital [
         <a href="#rid18">
          18
         </a>
         ]. An outbreak of
         <em>
          Mycobacterium chimaera
         </em>
         infection associated with contaminated Sorin 3T heater cooler devices used in cardiopulmonary bypass has affected patients with ventricular assist devices, but no infections in heart or lung transplant patients were reported [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
         In SOT recipients, the median onset of NTM infection is usually a year or more after transplantation [
         <a href="#rid6">
          6,11,17,20,21
         </a>
         ]. A large retrospective study of all lung and heart-lung transplant recipients at a single center in Australia over a 12-year period was performed to better define the epidemiology of NTM infection in this population [
         <a href="#rid11">
          11
         </a>
         ]. The following findings were noted:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Of 261 transplants, 23 cases of mycobacterial disease were detected (9 percent), only two of which were caused by TB. One of the patients with TB was co-infected with MAC.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The most common site of infection was the lungs (19 cases [83 percent]).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thirteen cases (57 percent) were caused by MAC. Other NTM species that caused disease were
         <em>
          M. haemophilum
         </em>
         (five cases),
         <em>
          M. abscessus
         </em>
         (three cases),
         <em>
          M. kansasii
         </em>
         (one case), and
         <em>
          M. asiaticum
         </em>
         (one case).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The median time to diagnosis of NTM infection following transplantation was 450 days (range 50 to 3272 days); this is much later than the median time to onset of TB. (See
         <a class="medical medical_review" href="/z/d/html/1407.html" rel="external">
          "Tuberculosis in solid organ transplant candidates and recipients", section on 'Timing following transplantation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Although no deaths were attributed to mycobacterial infection, many patients with MAC experienced a decline in pulmonary function that persisted despite treatment of the infection. Thus, infection with MAC should be considered in the differential diagnosis of chronic allograft dysfunction. (See
         <a class="local">
          'Outcomes'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         A retrospective study of all solid organ transplant recipients at a United States center over a 7.5-year period found 34 cases of NTM infection [
         <a href="#rid14">
          14
         </a>
         ]. These included 6 single lung, 13 bilateral lung, 8 heart, 4 liver, and 2 kidney transplant recipients, as well as 1 pancreas-kidney transplant recipient. Twenty-four of the 34 patients were male, median age was 55 years, and median time of occurrence was 8 months post-transplant.
         <em>
          M. abscessus
         </em>
         and MAC were the most common pathogens, and lung was the most frequent site of infection.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          CLINICAL FINDINGS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical presentation of NTM disease depends upon the infecting species, the site(s) of involvement, and whether the infection is localized or disseminated.
        </p>
        <p>
         Pleuropulmonary disease is the most common manifestation of NTM infection after transplantation, and lung transplant recipients are most commonly affected [
         <a href="#rid11">
          11
         </a>
         ]. Patients with NTM involving the lungs usually present with respiratory signs and symptoms such as chronic cough, sputum production, and, occasionally, hemoptysis. Disease can be fibrocavitary, nodular/bronchiectatic, or a combination of both [
         <a href="#rid3">
          3,6,11
         </a>
         ]. Patients may present with radiographic abnormalities such as pulmonary nodules or tree-in-bud opacities on chest computed tomography. In a small case-control study, larger opacities (&gt;2 cm) and cavitary nodules were more common in immunocompromised patients than in immunocompetent patients [
         <a href="#rid22">
          22
         </a>
         ].
         <em>
          M. avium
         </em>
         complex (MAC),
         <em>
          M. kansasii
         </em>
         ,
         <em>
          M. abscessus
         </em>
         , and
         <em>
          Mycobacterium xenopi
         </em>
         are the most common causes of pulmonary disease [
         <a href="#rid3">
          3,6,11
         </a>
         ].
         <em>
          M. kansasii
         </em>
         , in particular, can cause aggressive disease in lung transplant recipients and often mimics reactivated pulmonary tuberculosis (TB), including cavitary infiltrates with an upper-lobe predilection [
         <a href="#rid12">
          12
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5342.html" rel="external">
          "Overview of nontuberculous mycobacterial infections"
         </a>
         .)
        </p>
        <p>
         Cutaneous, musculoskeletal (including tenosynovitis and septic arthritis), and disseminated infections are the next most common presentations, and the most common presentations among non-lung solid organ transplant recipients [
         <a href="#rid6">
          6,13,23
         </a>
         ]. Disseminated infection caused by MAC and other NTM typically presents with constitutional symptoms (weight loss, fever, night sweats); although notably, in the SOT population with disseminated disease, these symptoms are frequently absent [
         <a href="#rid6">
          6,20
         </a>
         ]. In a systematic review of renal transplant patients with NTM, disseminated disease was the most common manifestation, affecting 40 percent of patients [
         <a href="#rid24">
          24
         </a>
         ].
         <em>
          M. abscessus,
         </em>
         <em>
          M. chelonae,
         </em>
         and
         <em>
          M. kansasii
         </em>
         are the NTM species most frequently associated with disseminated infections in solid organ transplant recipients [
         <a href="#rid5">
          5,6
         </a>
         ]. Interestingly, MAC infection in organ transplant recipients can primarily involve the allograft. There are case reports of MAC causing acute interstitial nephritis in renal transplant recipients and hepatic infection in liver transplant recipients [
         <a href="#rid25">
          25,26
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5342.html" rel="external">
          "Overview of nontuberculous mycobacterial infections"
         </a>
         .)
        </p>
        <p>
         The clinical spectrum of disease caused by the rapidly growing mycobacteria (
         <em>
          M. fortuitum
         </em>
         ,
         <em>
          M. chelonae
         </em>
         , and
         <em>
          M. abscessus
         </em>
         ) varies depending upon the species.
         <em>
          M. fortuitum
         </em>
         and the slow-growing
         <em>
          M. marinum
         </em>
         tend to cause localized skin infections, which disseminate infrequently. These may present as papules or nodules (frequently with purple discoloration).
         <em>
          M. marinum
         </em>
         infection is commonly known as fish-tank granuloma and usually occurs after exposure to aquariums or marine environments [
         <a href="#rid27">
          27
         </a>
         ]. Skin infection with the rapidly growing mycobacteria may result in recurrent abscesses or chronic draining sinuses. (See
         <a class="medical medical_review" href="/z/d/html/5347.html" rel="external">
          "Rapidly growing mycobacterial infections: Mycobacteria abscessus, chelonae, and fortuitum"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5344.html" rel="external">
          "Epidemiology of nontuberculous mycobacterial infections"
         </a>
         .)
        </p>
        <p>
         <em>
          M. abscessus
         </em>
         tends to be particularly virulent and can cause pulmonary, cutaneous, surgical site or prosthetic device infection, and/or disseminated disease. Several cases of fatal post-transplant
         <em>
          M. abscessus
         </em>
         infection involving the lungs and/or pleural space have been reported in lung transplant recipients [
         <a href="#rid7">
          7,28-34
         </a>
         ]; severe cases have also been reported in renal, heart, and multivisceral transplant recipients [
         <a href="#rid35">
          35,36
         </a>
         ]. A retrospective study of patients with cystic fibrosis found that colonization with
         <em>
          M. abscessus
         </em>
         prior to transplantation strongly predicted invasive disease as compared with isolation of other NTM species (odds ratio 7.45, 95% CI 2.9-16.9); this association was not observed for other NTM species [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
         In an international survey of lung transplant centers,
         <em>
          M. abscessus
         </em>
         infections were identified in 17 of 5200 patients (0.33 percent) [
         <a href="#rid31">
          31
         </a>
         ]. Eleven of 16 patients (73 percent) who were treated had a radiographic or microbiologic response to therapy, and two died from the infection. Two patients had late recurrence of infection at a distant site following cessation of therapy.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because of the rarity and protean manifestations of NTM infection in the SOT population, it is crucial to maintain a high index of suspicion so timely diagnosis can be made and appropriate treatment started. NTM should be considered in solid organ transplant recipients with pulmonary complaints, especially lung transplant recipients. Staining and culture for acid-fast bacilli (AFB) should be performed on all bronchoscopy specimens. In addition, mycobacterial infections should be considered in transplant recipients with atypical skin lesions or soft tissue infections, including surgical site infections. Skin biopsy should be performed in all patients with suspicious lesions and should be sent for AFB staining and culture as well as histopathology.
        </p>
        <p>
         Some NTM species require specialized media, temperatures, or longer duration of incubation for growth; an awareness of this and potentially alerting the microbiology lab of suspicions can be paramount in making the appropriate diagnosis (see
         <a class="medical medical_review" href="/z/d/html/5343.html" rel="external">
          "Microbiology of nontuberculous mycobacteria"
         </a>
         ). Nucleic acid probes are available for identification of some NTM (ie,
         <em>
          M. avium
         </em>
         complex and
         <em>
          M. kansasii
         </em>
         ); molecular methods can be used for the species/subspecies identification of rapidly growing mycobacteria (RGM). Sequence-based identification, often with the 16S rRNA gene as target, or matrix-assisted laser desorption ionization-time-of-flight mass spectrometry (MALDI-TOF MS) are being increasingly utilized as methods to more rapidly identify organisms [
         <a href="#rid6">
          6
         </a>
         ]. In RGM, identification of an inducible macrolide-resistance gene (
         <em>
          erm
         </em>
         gene
         <em>
          )
         </em>
         is important in guiding treatment decisions
         <em>
          .
         </em>
         (See
         <a class="medical medical_review" href="/z/d/html/5346.html" rel="external">
          "Diagnosis of nontuberculous mycobacterial infections of the lungs"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5347.html" rel="external">
          "Rapidly growing mycobacterial infections: Mycobacteria abscessus, chelonae, and fortuitum"
         </a>
         .)
        </p>
        <p>
         Because NTM can be found as environmental or laboratory contaminants and can transiently colonize the lungs, a positive culture from a non-sterile site such as from bronchoalveolar lavage (BAL) fluid does not necessarily indicate infection. In a cohort study of 237 lung transplant recipients, NTM were isolated from 53 patients (22.4 percent), but only 6 patients required treatment (2 met criteria for pulmonary disease and 4 had surgical site infections) [
         <a href="#rid37">
          37
         </a>
         ]. Although the incidence rate of NTM isolation was 9.0 per 100 person-years, that of NTM disease was only 1.1 per 100 person-years [
         <a href="#rid37">
          37
         </a>
         ]. The burden of organisms recovered, the specific NTM species involved, and clinical and radiographic signs and symptoms should be considered when defining the approach to treatment [
         <a href="#rid23">
          23
         </a>
         ]. For example, since
         <em>
          M. abscessus
         </em>
         is particularly virulent, the isolation of this species from a post-transplant sputum culture should warrant an aggressive evaluation and careful consideration of treatment.
        </p>
        <p>
         Specific criteria exist for establishing the diagnosis of NTM pulmonary disease, as outlined in the table  (
         <a class="graphic graphic_table graphicRef61404" href="/z/d/graphic/61404.html" rel="external">
          table 2
         </a>
         ); these criteria are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5346.html" rel="external">
          "Diagnosis of nontuberculous mycobacterial infections of the lungs", section on 'Diagnostic criteria'
         </a>
         .)
        </p>
        <p>
         There are limited data for applying these criteria to SOT patients, but it is reasonable to use them as a framework for diagnosis of NTM pulmonary disease in this population.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         For solid organ transplant recipients with disease caused by NTM, recommendations for initial management are similar to those for the general population and involve combination therapy with multiple antimycobacterial agents [
         <a href="#rid12">
          12
         </a>
         ]. There have been no randomized trials of treatment of NTM in solid organ transplant recipients, and data regarding response to therapy among transplant recipients are limited to case series and case reports [
         <a href="#rid11">
          11,20,25-33,35,38-42
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5341.html" rel="external">
          "Treatment of
          <i>
           Mycobacterium avium
          </i>
          complex pulmonary infection in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5347.html" rel="external">
          "Rapidly growing mycobacterial infections: Mycobacteria abscessus, chelonae, and fortuitum"
         </a>
         .)
        </p>
        <p>
         The following issues regarding management in solid organ transplant recipients should be noted:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Interactions between antimycobacterial agents and both calcineurin inhibitors and rapamycin (
         <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">
          sirolimus
         </a>
         ) exist and must be taken into account when choosing a regimen [
         <a href="#rid3">
          3
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The rifamycins, particularly
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         (also known as rifampicin), reduce serum concentrations of
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         ,
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         , rapamycin (
         <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">
          sirolimus
         </a>
         ), and
         <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">
          everolimus
         </a>
         via induction of cytochrome p450 isoenzyme CYP3A4, and their use has been associated with the development of rejection. (See
         <a class="medical medical_review" href="/z/d/html/1407.html" rel="external">
          "Tuberculosis in solid organ transplant candidates and recipients", section on 'Management of active tuberculosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Certain macrolides, such as
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         , can lead to increased serum concentrations of the calcineurin inhibitors and rapamycin via cytochrome p450 inhibition [
         <a href="#rid43">
          43,44
         </a>
         ].
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          Azithromycin
         </a>
         is less likely to cause this effect, although calcineurin inhibitor and rapamycin levels should be monitored closely in all patients receiving any macrolide [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Although there are no specific recommendations regarding the duration of antimycobacterial therapy in solid organ transplant recipients, such patients often require a longer course than immunocompetent hosts in order to prevent relapse [
         <a href="#rid3">
          3
         </a>
         ]. For example, in immunocompetent hosts with
         <em>
          M. avium
         </em>
         complex pulmonary infection, 12 months of therapy following negative sputum cultures is recommended, but this should be the minimum treatment duration among solid organ transplant recipients. In patients in whom immunosuppression cannot be reduced or in whom there is a high burden of disease, prolonged therapy may be necessary. For soft tissue or bone disease due to NTM, at least four to six months of therapy are recommended [
         <a href="#rid12">
          12,45
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5341.html" rel="external">
          "Treatment of
          <i>
           Mycobacterium avium
          </i>
          complex pulmonary infection in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ongoing disease surveillance with follow up imaging and microbiologic testing whenever possible can be helpful in determining duration of therapy. In addition, relapse or reinfection can occur after completion of therapy so patients should have ongoing clinical and microbiologic monitoring where possible.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intermittent or thrice weekly oral antibiotic regimens, such as those recommended to treat nodular bronchiectatic pulmonary MAC infection in the general population, should be avoided in the SOT population due to the potential for fluctuating levels of immunosuppression with thrice weekly antibiotics and also the potential absorption issues associated with complications of lung transplantation specifically.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The intensity of the immunosuppressive regimen should be reduced whenever possible [
         <a href="#rid3">
          3,6
         </a>
         ]. Immune reconstitution inflammatory syndrome, typically characterized by an unexplained worsening after initial improvement, can occur when immunosuppressive regimens are reduced [
         <a href="#rid46">
          46
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3762.html" rel="external">
          "Immune reconstitution inflammatory syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Susceptibility testing of NTM can be particularly helpful in managing infections with NTM in solid organ transplant recipients given the potential for drug interactions and toxicities, although the ability of in vitro susceptibility testing to predict treatment outcomes varies depending on NTM species [
         <a href="#rid3">
          3,4,6
         </a>
         ]. Susceptibility testing should be performed routinely; the agents that should be included in susceptibility testing vary depending upon which species is isolated. In addition to determining the optimal initial regimens, such testing is important for tailoring therapy to an oral regimen once control of the infection has been achieved. It is important to have susceptibility testing done in a laboratory with expertise in evaluating NTM species. (See
         <a class="medical medical_review" href="/z/d/html/5343.html" rel="external">
          "Microbiology of nontuberculous mycobacteria"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5347.html" rel="external">
          "Rapidly growing mycobacterial infections: Mycobacteria abscessus, chelonae, and fortuitum", section on 'Susceptibility testing'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5341.html" rel="external">
          "Treatment of
          <i>
           Mycobacterium avium
          </i>
          complex pulmonary infection in adults", section on 'Antimicrobial susceptibility testing'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Surgical resection of localized skin lesions can be used as an adjunct to medical therapy in the setting of abscess formation, to debulk areas with a large burden of disease, and/or in patients who have not responded to antimycobacterial therapy [
         <a href="#rid4">
          4,21
         </a>
         ]. Surgical source control and/or removal of infected prosthetic devices is especially important for surgical site infections.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          OUTCOMES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The outcomes of NTM infections among solid organ transplant recipients have not been well established given the low rates of infection. These infections are often difficult to treat. Reported cure rates range from 32 to 44 percent, although a greater percentage have some clinical improvement with NTM therapy [
         <a href="#rid3">
          3
         </a>
         ]. Outcomes in SOTs are highly variable and depend on the extent of infection, susceptibility of the organism and level of immunosuppression of the host [
         <a href="#rid3">
          3,15,24
         </a>
         ].
        </p>
        <p>
         A cohort study of 33 solid organ transplant recipients with NTM infections at a single United States center found a significant association between early NTM infection and three-year post-transplant mortality. Interestingly, patients with
         <em>
          M. abscessus
         </em>
         infections did not have increased mortality compared with those with other NTM infections
         <em>
          .
         </em>
         Also of interest was that NTM colonization was listed as a cause of death in a minority of patients, suggesting that other factors impact mortality more directly [
         <a href="#rid47">
          47
         </a>
         ]. Immunomodulatory effects of the infection, rejection, or development of secondary nosocomial infections were all thought to contribute to mortality in this cohort.
        </p>
        <p>
         Reports of outcomes of NTM infection in lung transplant patients are mixed. In a retrospective study that included 13 lung transplant recipients with
         <em>
          M. avium
         </em>
         complex (MAC) pulmonary infection, none died from MAC [
         <a href="#rid11">
          11
         </a>
         ]. However, among eight patients who were treated with antimycobacterial therapy for more than two months, most had no improvement in graft function following therapy.
        </p>
        <p>
         A retrospective review of 201 lung transplant recipients found nine with post-transplant NTM disease and 27 with NTM colonization. NTM colonization was a risk factor for NTM disease (hazard ratio [HR] 8.39, 95% CI 2.08-33.85) and presence of either colonization or disease significantly increased the risk of death after lung transplant even when controlling for factors such as bronchiolitis obliterans syndrome (adjusted HR 2.18, 95% CI 1.26-3.76) [
         <a href="#rid15">
          15
         </a>
         ]. Notably, cause of death was more commonly related to a non-NTM infection. A recently published meta-analysis found that NTM disease, but not colonization, was associated with increased mortality (HR 2.69, 95% CI 1.70-4.26) and chronic lung allograft dysfunction (CLAD) (HR 2.11, 95% CI 1.03-4.35) [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
         As described above,
         <em>
          M. abscessus
         </em>
         can be particularly aggressive in lung transplant recipients, sometimes leading to relapse even after long courses of antimicrobial therapy or death [
         <a href="#rid28">
          28
         </a>
         ]. (See
         <a class="local">
          'Clinical findings'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          PREVENTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The possible efficacy of prophylaxis in transplant candidates or recipients colonized with NTM species has not been established. There is wide variation in the management of solid organ transplant candidates known to be colonized with NTM species, ranging from no therapy to pre- and/or peri-transplant prophylaxis [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         In lung transplant candidates who are colonized or infected with
         <em>
          M. avium
         </em>
         complex (MAC), multidrug MAC therapy should be considered prior to lung transplantation to reduce overall burden of disease [
         <a href="#rid6">
          6
         </a>
         ]. The optimal duration of antibiotic therapy prior to transplant or in post-transplant period is unknown. The duration of therapy both prior to and following transplantation must be individualized. Our practice is to start patients on antibiotics prior to transplant at least at the time of listing and likely prior. Duration of therapy post-transplant is driven by intra-operative cultures at the time of transplant and early recipient BAL cultures. If these remain negative, we generally treat for 6 to 12 weeks post-transplant. (See
         <a class="medical medical_review" href="/z/d/html/5341.html" rel="external">
          "Treatment of
          <i>
           Mycobacterium avium
          </i>
          complex pulmonary infection in adults", section on 'Initial treatment'
         </a>
         .)
        </p>
        <p>
         Although successful treatment has been achieved in some lung transplant recipients with
         <em>
          M. abscessus
         </em>
         infection, lung transplantation in individuals known to be colonized, particularly those with cystic fibrosis, remains controversial. This is especially true for infections caused by
         <em>
          M. abscessus
         </em>
         subspecies
         <em>
          abscessus
         </em>
         , which is particularly virulent (see
         <a class="local">
          'Clinical findings'
         </a>
         above). The presence of
         <em>
          M. abscessus
         </em>
         on cultures pretransplant is associated with increased postoperative morbidity, including thoracic cavity infections and sternal wound infections [
         <a href="#rid31">
          31-33,48
         </a>
         ], although survival has not been significantly altered in single-center studies [
         <a href="#rid33">
          33,48-50
         </a>
         ]. If transplant is considered in a patient colonized or infected with
         <em>
          Mycobacterium abscessus
         </em>
         , it is important to prove that the patient is able to tolerate an effective multi-drug regimen and to demonstrate positive response to treatment prior to transplant. (See
         <a class="local">
          'Clinical findings'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H99142889">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113062.html" rel="external">
          "Society guideline links: Nontuberculous mycobacteria"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/117424.html" rel="external">
          "Society guideline links: Infections in solid organ transplant recipients"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mycobacterium species
         </strong>
         –
         <strong>
         </strong>
         <em>
          Mycobacterium avium
         </em>
         and
         <em>
          Mycobacterium intracellulare
         </em>
         (together known as
         <em>
          Mycobacterium avium
         </em>
         complex [MAC]) are the most common nontuberculous mycobacterial (NTM) species isolated after solid organ transplantation and typically involve the lungs. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentation
         </strong>
         –
         <strong>
         </strong>
         The clinical presentation of NTM disease depends on the infecting species, the site(s) of involvement, and whether the infection is localized or disseminated. Pleuropulmonary disease is the most common manifestation of NTM infection among solid organ transplant recipients, occurring in over 50 percent of cases. (See
         <a class="local">
          'Clinical findings'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          When to suspect the diagnosis –
         </strong>
         NTM should be considered in solid organ transplant recipients with pulmonary complaints. Staining and culture for acid-fast bacilli should be performed on all bronchoscopy specimens. In addition, mycobacterial infections should be considered in solid organ transplant recipients with atypical skin lesions or soft tissue infections. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnostic criteria
         </strong>
         –
         <strong>
         </strong>
         Specific criteria exist for establishing the diagnosis of NTM pulmonary disease as outlined in the table  (
         <a class="graphic graphic_table graphicRef61404" href="/z/d/graphic/61404.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5346.html" rel="external">
          "Diagnosis of nontuberculous mycobacterial infections of the lungs", section on 'Diagnostic criteria'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment regimens
         </strong>
         –
         <strong>
         </strong>
         For solid organ transplant recipients with disease caused by nontuberculous mycobacteria, we suggest similar initial antimycobacterial regimens to those used in immunocompetent hosts (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other aspects of treatment
         </strong>
         –
         <strong>
         </strong>
         The following issues regarding management in solid organ transplant recipients should be noted:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Drug interactions
         </strong>
         –
         <strong>
         </strong>
         Interactions between antimycobacterial agents and calcineurin inhibitors exist and must be taken into account when choosing a regimen. The most significant interaction is between the rifamycins and both the calcineurin inhibitors and rapamycin. Certain macrolides, such as
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         , also interact significantly with both the calcineurin inhibitors and rapamycin.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Duration of therapy
         </strong>
         –
         <strong>
         </strong>
         Solid organ transplant recipients often require a longer course than immunocompetent hosts in order to prevent relapse.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Adjusting immunosuppression
         </strong>
         –
         <strong>
         </strong>
         The intensity of the immunosuppressive regimen should be reduced whenever possible. Immune reconstitution inflammatory response syndrome can occur when immunosuppressive regimens are reduced.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Susceptibility testing
         </strong>
         –
         <strong>
         </strong>
         Susceptibility testing can be particularly helpful in managing NTM infections in solid organ transplant recipients given the potential for drug interactions and toxicities. The agents that should be included in susceptibility testing vary depending upon which species is isolated.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Adjunctive surgery
         </strong>
         –
         <strong>
         </strong>
         Surgical resection of localized skin lesions can be used as an adjunct to medical therapy in the setting of abscess formation, to debulk areas with a large burden of disease, and/or in patients who have not responded to antimycobacterial therapy. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          MAC in lung transplant candidates
         </strong>
         –
         <strong>
         </strong>
         For lung transplant candidates who are colonized or infected with
         <em>
          M. avium
         </em>
         complex, we suggest multidrug MAC therapy prior to and following lung transplantation (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Prevention'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Matsumoto Y, Kinjo T, Motooka D, et al. Comprehensive subspecies identification of 175 nontuberculous mycobacteria species based on 7547 genomic profiles. Emerg Microbes Infect 2019; 8:1043.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adjemian J, Olivier KN, Seitz AE, et al. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med 2012; 185:881.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doucette K, Fishman JA. Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients. Clin Infect Dis 2004; 38:1428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daley CL. Nontuberculous mycobacterial disease in transplant recipients: early diagnosis and treatment. Curr Opin Organ Transplant 2009; 14:619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piersimoni C. Nontuberculous mycobacteria infection in solid organ transplant recipients. Eur J Clin Microbiol Infect Dis 2012; 31:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Longworth SA, Daly JS, AST Infectious Diseases Community of Practice. Management of infections due to nontuberculous mycobacteria in solid organ transplant recipients-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019; 33:e13588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aitken ML, Limaye A, Pottinger P, et al. Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center. Am J Respir Crit Care Med 2012; 185:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bryant JM, Grogono DM, Greaves D, et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet 2013; 381:1551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bryant JM, Grogono DM, Rodriguez-Rincon D, et al. Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. Science 2016; 354:751.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           George IA, Santos CA, Olsen MA, Bailey TC. Epidemiology and Outcomes of Nontuberculous Mycobacterial Infections in Solid Organ Transplant Recipients at a Midwestern Center. Transplantation 2016; 100:1073.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malouf MA, Glanville AR. The spectrum of mycobacterial infection after lung transplantation. Am J Respir Crit Care Med 1999; 160:1611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daley CL, Iaccarino JM, Lange C, et al. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clin Infect Dis 2020; 71:e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knoll BM. Update on nontuberculous mycobacterial infections in solid organ and hematopoietic stem cell transplant recipients. Curr Infect Dis Rep 2014; 16:421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Longworth SA, Vinnard C, Lee I, et al. Risk factors for nontuberculous mycobacterial infections in solid organ transplant recipients: a case-control study. Transpl Infect Dis 2014; 16:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang HC, Weigt SS, Derhovanessian A, et al. Non-tuberculous mycobacterium infection after lung transplantation is associated with increased mortality. J Heart Lung Transplant 2011; 30:790.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marty PK, Yetmar ZA, Gerberi DJ, et al. Risk factors and outcomes of non-tuberculous mycobacteria infection in lung transplant recipients: A systematic review and meta-analysis. J Heart Lung Transplant 2023; 42:264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mejia-Chew C, Carver PL, Rutjanawech S, et al. Risk Factors for Nontuberculous Mycobacteria Infections in Solid Organ Transplant Recipients: A Multinational Case-Control Study. Clin Infect Dis 2023; 76:e995.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baker AW, Lewis SS, Alexander BD, et al. Two-Phase Hospital-Associated Outbreak of Mycobacterium abscessus: Investigation and Mitigation. Clin Infect Dis 2017; 64:902.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balsam LB, Louie E, Hill F, et al. Mycobacterium chimaera left ventricular assist device infections. J Card Surg 2017; 32:402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel R, Roberts GD, Keating MR, Paya CV. Infections due to nontuberculous mycobacteria in kidney, heart, and liver transplant recipients. Clin Infect Dis 1994; 19:263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keating MR, Daly JS, AST Infectious Diseases Community of Practice. Nontuberculous mycobacterial infections in solid organ transplantation. Am J Transplant 2013; 13 Suppl 4:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee Y, Song JW, Chae EJ, et al. CT findings of pulmonary non-tuberculous mycobacterial infection in non-AIDS immunocompromised patients: a case-controlled comparison with immunocompetent patients. Br J Radiol 2013; 86:20120209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abad CL, Razonable RR. Non-tuberculous mycobacterial infections in solid organ transplant recipients: An update. J Clin Tuberc Other Mycobact Dis 2016; 4:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Song Y, Zhang L, Yang H, et al. Nontuberculous mycobacterium infection in renal transplant recipients: a systematic review. Infect Dis (Lond) 2018; 50:409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rawla MS, Kozak A, Hadley S, LeCates WW. Mycobacterium avium-intracellulare-associated acute interstitial nephritis: a rare cause of renal allograft dysfunction. Transpl Infect Dis 2009; 11:529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singhal A, Gates C, Malhotra N, et al. Successful management of primary nontuberculous mycobacterial infection of hepatic allograft following orthotopic liver transplantation for hepatitis C. Transpl Infect Dis 2011; 13:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pandian TK, Deziel PJ, Otley CC, et al. Mycobacterium marinum infections in transplant recipients: case report and review of the literature. Transpl Infect Dis 2008; 10:358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanguinetti M, Ardito F, Fiscarelli E, et al. Fatal pulmonary infection due to multidrug-resistant Mycobacterium abscessus in a patient with cystic fibrosis. J Clin Microbiol 2001; 39:816.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fairhurst RM, Kubak BM, Shpiner RB, et al. Mycobacterium abscessus empyema in a lung transplant recipient. J Heart Lung Transplant 2002; 21:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor JL, Palmer SM. Mycobacterium abscessus chest wall and pulmonary infection in a cystic fibrosis lung transplant recipient. J Heart Lung Transplant 2006; 25:985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chernenko SM, Humar A, Hutcheon M, et al. Mycobacterium abscessus infections in lung transplant recipients: the international experience. J Heart Lung Transplant 2006; 25:1447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chalermskulrat W, Sood N, Neuringer IP, et al. Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation. Thorax 2006; 61:507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaidi S, Elidemir O, Heinle JS, et al. Mycobacterium abscessus in cystic fibrosis lung transplant recipients: report of 2 cases and risk for recurrence. Transpl Infect Dis 2009; 11:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Osmani M, Sotello D, Alvarez S, et al. Mycobacterium abscessus infections in lung transplant recipients: 15-year experience from a single institution. Transpl Infect Dis 2018; 20:e12835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garrison AP, Morris MI, Doblecki Lewis S, et al. Mycobacterium abscessus infection in solid organ transplant recipients: report of three cases and review of the literature. Transpl Infect Dis 2009; 11:541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silva JT, López-Medrano F, Fernández-Ruiz M, et al. Mycobacterium abscessus pulmonary infection complicated with vertebral osteomyelitis in a heart transplant recipient: case report and literature review. Transpl Infect Dis 2015; 17:418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knoll BM, Kappagoda S, Gill RR, et al. Non-tuberculous mycobacterial infection among lung transplant recipients: a 15-year cohort study. Transpl Infect Dis 2012; 14:452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kesten S, Chaparro C. Mycobacterial infections in lung transplant recipients. Chest 1999; 115:741.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woo MS, Downey S, Inderlied CB, et al. Pediatric transplant grand rounds. A case presentation: skin lesions in a post-lung transplant patient. Pediatr Transplant 1997; 1:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swetter SM, Kindel SE, Smoller BR. Cutaneous nodules of Mycobacterium chelonae in an immunosuppressed patient with preexisting pulmonary colonization. J Am Acad Dermatol 1993; 28:352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baldi S, Rapellino M, Ruffini E, et al. Atypical mycobacteriosis in a lung transplant recipient. Eur Respir J 1997; 10:952.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Torres F, Hodges T, Zamora MR. Mycobacterium marinum infection in a lung transplant recipient. J Heart Lung Transplant 2001; 20:486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sádaba B, López de Ocáriz A, Azanza JR, et al. Concurrent clarithromycin and cyclosporin A treatment. J Antimicrob Chemother 1998; 42:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Capone D, Palmiero G, Gentile A, et al. A pharmacokinetic interaction between clarithromycin and sirolimus in kidney transplant recipient. Curr Drug Metab 2007; 8:379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haworth CS, Banks J, Capstick T, et al. British Thoracic Society Guideline for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). BMJ Open Respir Res 2017; 4:e000242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lemoine M, Laurent C, Hanoy M, et al. Immune Reconstitution Inflammatory Syndrome Secondary to Mycobacterium kansasii Infection in a Kidney Transplant Recipient. Am J Transplant 2015; 15:3255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Longworth SA, Blumberg EA, Barton TD, Vinnard C. Non-tuberculous mycobacterial infections after solid organ transplantation: a survival analysis. Clin Microbiol Infect 2015; 21:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qvist T, Pressler T, Thomsen VO, et al. Nontuberculous mycobacterial disease is not a contraindication to lung transplantation in patients with cystic fibrosis: a retrospective analysis in a Danish patient population. Transplant Proc 2013; 45:342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lobo LJ, Chang LC, Esther CR Jr, et al. Lung transplant outcomes in cystic fibrosis patients with pre-operative Mycobacterium abscessus respiratory infections. Clin Transplant 2013; 27:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perez AA, Singer JP, Schwartz BS, et al. Management and clinical outcomes after lung transplantation in patients with pre-transplant Mycobacterium abscessus infection: A single center experience. Transpl Infect Dis 2019; 21:e13084.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1413 Version 21.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31287781" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Comprehensive subspecies identification of 175 nontuberculous mycobacteria species based on 7547 genomic profiles.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22312016" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15156482" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19745733" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Nontuberculous mycobacterial disease in transplant recipients: early diagnosis and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21732201" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Nontuberculous mycobacteria infection in solid organ transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31077618" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Management of infections due to nontuberculous mycobacteria in solid organ transplant recipients-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22246710" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23541540" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27846606" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26950719" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Epidemiology and Outcomes of Nontuberculous Mycobacterial Infections in Solid Organ Transplant Recipients at a Midwestern Center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10556129" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The spectrum of mycobacterial infection after lung transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32628747" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24980388" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Update on nontuberculous mycobacterial infections in solid organ and hematopoietic stem cell transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24350627" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Risk factors for nontuberculous mycobacterial infections in solid organ transplant recipients: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21482148" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Non-tuberculous mycobacterium infection after lung transplantation is associated with increased mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36334962" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Risk factors and outcomes of non-tuberculous mycobacteria infection in lung transplant recipients: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35879465" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Risk Factors for Nontuberculous Mycobacteria Infections in Solid Organ Transplant Recipients: A Multinational Case-Control Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28077517" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Two-Phase Hospital-Associated Outbreak of Mycobacterium abscessus: Investigation and Mitigation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28508409" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Mycobacterium chimaera left ventricular assist device infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7986898" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Infections due to nontuberculous mycobacteria in kidney, heart, and liver transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23465001" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Nontuberculous mycobacterial infections in solid organ transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23440166" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : CT findings of pulmonary non-tuberculous mycobacterial infection in non-AIDS immunocompromised patients: a case-controlled comparison with immunocompetent patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31723683" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Non-tuberculous mycobacterial infections in solid organ transplant recipients: An update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29400108" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Nontuberculous mycobacterium infection in renal transplant recipients: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19659671" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Mycobacterium avium-intracellulare-associated acute interstitial nephritis: a rare cause of renal allograft dysfunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20534034" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Successful management of primary nontuberculous mycobacterial infection of hepatic allograft following orthotopic liver transplantation for hepatitis C.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18482202" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Mycobacterium marinum infections in transplant recipients: case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11158161" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Fatal pulmonary infection due to multidrug-resistant Mycobacterium abscessus in a patient with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11897529" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Mycobacterium abscessus empyema in a lung transplant recipient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16890122" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Mycobacterium abscessus chest wall and pulmonary infection in a cystic fibrosis lung transplant recipient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17178340" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Mycobacterium abscessus infections in lung transplant recipients: the international experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16601086" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19298240" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Mycobacterium abscessus in cystic fibrosis lung transplant recipients: report of 2 cases and risk for recurrence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29359872" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Mycobacterium abscessus infections in lung transplant recipients: 15-year experience from a single institution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19671119" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Mycobacterium abscessus infection in solid organ transplant recipients: report of three cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25816889" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Mycobacterium abscessus pulmonary infection complicated with vertebral osteomyelitis in a heart transplant recipient: case report and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22676720" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Non-tuberculous mycobacterial infection among lung transplant recipients: a 15-year cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10084486" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Mycobacterial infections in lung transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10084776" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Pediatric transplant grand rounds. A case presentation: skin lesions in a post-lung transplant patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8436657" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Cutaneous nodules of Mycobacterium chelonae in an immunosuppressed patient with preexisting pulmonary colonization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9150340" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Atypical mycobacteriosis in a lung transplant recipient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11295588" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Mycobacterium marinum infection in a lung transplant recipient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9786481" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Concurrent clarithromycin and cyclosporin A treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17504225" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : A pharmacokinetic interaction between clarithromycin and sirolimus in kidney transplant recipient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29449949" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : British Thoracic Society Guideline for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26372924" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Immune Reconstitution Inflammatory Syndrome Secondary to Mycobacterium kansasii Infection in a Kidney Transplant Recipient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25636926" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Non-tuberculous mycobacterial infections after solid organ transplantation: a survival analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23267788" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Nontuberculous mycobacterial disease is not a contraindication to lung transplantation in patients with cystic fibrosis: a retrospective analysis in a Danish patient population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23710571" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Lung transplant outcomes in cystic fibrosis patients with pre-operative Mycobacterium abscessus respiratory infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30924986" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Management and clinical outcomes after lung transplantation in patients with pre-transplant Mycobacterium abscessus infection: A single center experience.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
